The distribution of patients with triple-negative breast cancer (TNBC) and hormone receptor-positive tumors (ER and/or PR positive) is approximately equal between the two study groups (intervention vs. control). This evidence concerns the gene NR4A1 and triple-negative breast carcinoma.